Jaguar Health

Jaguar Health's crofelemer, an Orphan-Drug designated plant-based prescription drug, is being evaluated in five clinical studies for MVID and SBS-IF in the US, EU, and MENA regions. The first Phase 2 study for pediatric MVID patients has initiated, with dosing expected in late 2024/early 2025 and initial proof-of-concept results potentially available in Q1 2025.

Jaguar Health initiated a Phase 2 study to evaluate crofelemer for Microvillus Inclusion Disease (MVID) in pediatric patients, part of five clinical efforts across US, EU, and MENA regions. First patient dosing expected between Dec 2024 and Jan 2025, with initial results potentially in Q1 2025. Crofelemer has Orphan-Drug Designation from FDA and EMA for MVID and SBS-IF, targeting a novel oral powder solution for MVID, an ultrarare pediatric disease with no approved treatments.

The FDA granted orphan-drug designation to crofelemer for cholera treatment. Cholera, a global health emergency, causes 1.3 to 4 million cases and 21,000 to 143,000 deaths yearly. Crofelemer, a plant-based drug, aims to treat cholera-induced diarrhea, offering development incentives and market exclusivity upon approval.

Jaguar Health's Napo Pharmaceuticals announced FDA granted orphan-drug designation to crofelemer for cholera diarrhea treatment. Crofelemer, a plant-based drug, previously received ODD for short bowel syndrome and microvillus inclusion disease. The designation offers development incentives and seven-year marketing exclusivity upon approval. Jaguar plans to pursue ODD for crofelemer from the EMA and orphan-drug designation for NP-300, a second-generation anti-secretory agent, for cholera diarrhea treatment.

The FDA granted orphan-drug designation to crofelemer for cholera diarrhea treatment. Cholera, a WHO grade 3 emergency, causes 1.3-4M cases and 21k-143k deaths annually. Crofelemer, from the Croton lechleri tree, aims to treat severe dehydration in cholera patients, offering development incentives and 7-year marketing exclusivity upon approval.

Ladenburg Thalmann hosts a Scientific Showcase on Dec 18, 2024, focusing on Jaguar Health's crofelemer clinical development for rare diseases MVID and SBS-IF. Five ongoing trials include three proof-of-concept and two Phase 2 studies across US, EU, and MENA. Initial results expected Q2 2025. Massimo Radaelli, CEO of Napo Therapeutics, named 'Best Pharmaceuticals Innovator of the Year - Europe'.

Jaguar Health initiates U.S. IIT to evaluate crofelemer for SBS-IF, part of five clinical efforts including three IIT proof-of-concept studies and two Phase 2 studies across US, EU, and MENA regions. Patient dosing expected Dec 2024-Q1 2025, with initial IIT results potentially in Q2 2025. Crofelemer has Orphan Drug Designation from FDA and EMA for SBS-IF and MVID.

Jaguar Health's Canalevia-CA1, the first and only FDA-conditionally approved treatment for chemotherapy-induced diarrhea in dogs, is featured in PetVet Magazine. The drug, containing crofelemer, addresses significant health concerns as cancer therapy-related diarrhea can impact treatment effectiveness. The same active ingredient is being studied in Jaguar's Phase 3 OnTarget trial for cancer therapy-related diarrhea in humans.